+Compare
BIIB
Stock ticker:
NASDAQ
AS OF
Sep 23 closing price
Price
$197.78
Change
-$2.84 (-1.42%)
Capitalization
28.7B

BIIB Price Prediction, Biogen AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar
GET INTRADAY SIGNALS
BIIB Trading results, last 6 months
AI Robots NameP/L
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Sep 23, 2022

BIIB in downward trend: 10-day moving average broke below 50-day moving average on August 26, 2022

The 10-day moving average for BIIB crossed bearishly below the 50-day moving average on August 26, 2022. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 21, 2022. You may want to consider selling the stock, shorting the stock, or exploring put options on BIIB as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BIIB turned negative on September 23, 2022. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

BIIB moved below its 50-day moving average on September 13, 2022 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BIIB broke above its upper Bollinger Band on September 09, 2022. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BIIB entered a downward trend on September 13, 2022. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BIIB's RSI Indicator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.417) is normal, around the industry mean (5.173). P/E Ratio (14.144) is within average values for comparable stocks, (90.169). BIIB's Projected Growth (PEG Ratio) (14.805) is very high in comparison to the industry average of (3.089). BIIB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.029). P/S Ratio (2.741) is also within normal values, averaging (3.618).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 69, placing this stock worse than average.

AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published Earnings

BIIB is expected to report earnings to fall 20.76% to $4.16 per share on October 25

Biogen BIIB Stock Earnings Reports
Q3'22
Est.
$4.16
Q2'22
Beat
by $1.19
Q1'22
Missed
by $0.72
Q4'21
Beat
by $0.01
Q3'21
Beat
by $0.68
The last earnings report on July 20 showed earnings per share of $5.25, beating the estimate of $4.06. With 1.44M shares outstanding, the current market capitalization sits at 28.70B.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Johnson & Johnson (NYSE:JNJ), Eli Lilly & Co (NYSE:LLY), ABBVIE (NYSE:ABBV), Pfizer (NYSE:PFE), Merck & Co (NYSE:MRK), AstraZeneca PLC (NASDAQ:AZN), Bristol-Myers Squibb Co (NYSE:BMY), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 71.41B. The market cap for tickers in the group ranges from 226K to 438.34B. JNJ holds the highest valuation in this group at 438.34B. The lowest valued company is NEWG at 226K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -2%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was -12%. RHHVF experienced the highest price growth at 3%, while GIFLF experienced the biggest fall at -24%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -32%. For the same stocks of the Industry, the average monthly volume growth was 51% and the average quarterly volume growth was 15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 19
P/E Growth Rating: 41
Price Growth Rating: 65
SMR Rating: 41
Profit Risk Rating: 69
Seasonality Score: -18 (-100 ... +100)
AI
View a ticker or compare two or three
BIIB
Buy/Sell Ratings
 
 
Technical Analysis# Of IndicatorsAvg. Odds
   
   
 
AI
A.I. Advisor
published General Information

General Information

a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Biotechnology
Address
225 Binney Street
Phone
+1 617 679-2000
Employees
9610
Web
http://www.biogen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KMDA4.500.05
+1.12%
Kamada Ltd
IR44.07-0.74
-1.65%
Ingersoll Rand
AMWD45.88-0.93
-1.99%
American Woodmark Corp
JAMF22.18-0.49
-2.16%
Jamf Holding Corp
QNGY0.21-0.01
-4.73%
Quanergy Systems

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with GILD. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then GILD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
-1.42%
GILD - BIIB
45%
Loosely correlated
-1.43%
AMGN - BIIB
39%
Loosely correlated
-0.34%
NVS - BIIB
37%
Loosely correlated
-1.46%
LLY - BIIB
36%
Loosely correlated
+0.19%
HZNP - BIIB
36%
Loosely correlated
+0.54%
More